Scientific Resources

Primary angle-closure glaucoma (PACG) represents a significant cause of blindness, affecting more than 17 million people worldwide. Moreover, the currently available treatment options for the management PACG remain relatively limited. The cilioscleral inter-positioning device is a novel minimally invasive implant designed to increase uveoscleral outflow without entering the chamber. This unique approach to lower IOP represents a new, efficient, and safe surgical option to reduce intraocular pressure for patients with PACG.

At the World Glaucoma Congress (WGC) in Rome, Italy this summer, Ciliatech presented preliminary results of the second 2-year postoperative clinical trial (SAFARI Ⅱ) on its Cilioscleral Interposition Device (CID).